Apple Boosts iPhone Exports from India by 76% Amid Supply Chain Shift

Published 5 hours agoAAPL

Apple Boosts iPhone Exports from India by 76% Amid Supply Chain Shift

Apple's exports of iPhones from India to the United States have soared, with a remarkable 76% increase in April 2025. In March 2025 alone, Apple exported iPhones valued at nearly ₹20,000 crore, equivalent to approximately $2.5 billion, contributing to a total of ₹1.5 lakh crore or about $18.75 billion in exports for the fiscal year 2024-25. This growth far exceeds Apple's initial targets under the Production-Linked Incentive scheme, doubling their projected goals, as noted by India Today.

Key to this growth is Apple's diversification of its supply chain, a move designed to circumvent potential tariffs on Chinese imports. Notably, Apple aims to shift all U.S.-bound iPhone manufacturing to India by the end of 2025. Furthermore, Foxconn, a crucial Apple supplier, has invested $1.5 billion in a new display module assembly facility near Chennai, expected to create around 14,000 jobs and support Apple's production needs, according to the Financial Times.

Additionally, these efforts are part of Apple's strategy to enhance its manufacturing base in response to trade policy threats, such as former President Donald Trump's proposed 25% tariff on Apple and Samsung devices unless production is moved to the U.S. Apple's increased manufacturing footprint in India not only mitigates the impact of Chinese tariffs but also aligns with India's 'Make in India' initiative, significantly boosting the nation's smartphone export sector, which saw exports rise to $16.5 billion in the 2023-24 fiscal year from $12 billion the previous year.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Biogen and City Therapeutics: No Recent RNAi Partnership Noted

Biogen and City Therapeutics: No Recent RNAi Partnership Noted

9 minutes agoBIIB

As of May 27, 2025, there is no publicly available information about a collaboration between Biogen and City Therapeutics to develop RNA interference (RNAi) therapies. While both companies are active in the biotech field, this specific partnership has not been reported. City Therapeutics has been focusing on strategic collaborations with other companies, like Bausch + Lomb, in developing RNAi-based treatments for retinal diseases, including geographic atrophy. Meanwhile, Biogen has forged partnerships, such as the one with C4 Therapeutics, to innovate in neuroscience drug discovery, Reuters reported. The absence of a partnership between Biogen and City Therapeutics for RNAi therapies does not overshadow the strategic alliances each company has formed in their respective areas. These partnerships highlight ongoing efforts to advance medical treatments through novel biotechnological approaches.

FHFA Ends Housing Policies, Impact on FICO Unclear

FHFA Ends Housing Policies, Impact on FICO Unclear

39 minutes agoFICO

Bill Pulte, Director of the Federal Housing Finance Agency (FHFA), has recently made waves by terminating certain policies. Notably, these include Special Purpose Credit Programs (SPCPs) and specific diversity, equity, and inclusion (DEI) initiatives at Fannie Mae and Freddie Mac. Though these policy changes have captured attention, there is no evidence linking them to fluctuations in FICO's stock price. FICO, famed for its credit scoring and analytics, operates independently from the FHFA's regulatory domain that includes government-sponsored enterprises like Fannie Mae and Freddie Mac. As such, any discontent expressed by FHFA officials typically doesn't reflect on FICO's stock performance, unlike entities directly overseen by the agency. For those monitoring FICO’s market activities, staying updated through financial news sources like National Mortgage News or through direct communication from FICO's investor relations remains the best approach. While FICO is indirectly affected by broader housing market shifts, its stock behavior is guided by different factors.

Nippon Steel to Acquire U.S. Steel in $14.1 Billion Deal

Nippon Steel to Acquire U.S. Steel in $14.1 Billion Deal

53 minutes agoX

Japan's Nippon Steel is moving forward with a deal to acquire U.S. Steel at $55 per share in a transaction valued at approximately $14.1 billion. This all-cash acquisition reflects an enterprise value of $14.9 billion, factoring in the existing debt. The announcement highlights a strategic partnership aimed at bolstering Nippon Steel's footprint in the American market. The proposal received overwhelming approval from U.S. Steel shareholders, with over 98% voting in favor as disclosed on April 12, 2024. However, the acquisition has faced hurdles, particularly from the Biden administration, which expressed national security concerns, prompting legal challenges and potentially delaying the executive order intended to block the merger. Notably, former President Donald Trump has voiced support for the transaction, emphasizing job creation and investment benefits, including maintaining U.S. Steel's headquarters in Pittsburgh. Nippon Steel has assured stakeholders that it plans to honor all existing labor agreements and will not pursue any layoffs or permanent plant closures as part of the merger. Meanwhile, U.S. Steel's stock responded positively, surging by 21% and hitting peak levels not seen since 2011, according to reports from El País. The deal's progress continues to unfold amidst complex political and economic considerations.

Eli Lilly Acquires SiteOne Therapeutics in $1 Billion Deal

Eli Lilly Acquires SiteOne Therapeutics in $1 Billion Deal

Eli Lilly has announced its acquisition of privately held SiteOne Therapeutics, a deal valued at up to $1 billion. This move will give Eli Lilly access to SiteOne's promising experimental non-opioid pain treatment known as STC-004. Reuters reported that this acquisition involves both an upfront cash payment and potential milestone-based payments, which are contingent on hitting regulatory and commercial milestones. The focus of STC-004 is on being a Nav1.8 inhibitor, which targets the channels involved in the transmission of pain signals. This method is akin to the approach used by Vertex Pharmaceuticals with its drug Journavx, which recently gained approval. The inclusion of STC-004 in Eli Lilly's arsenal could enhance its offerings in the non-opioid pain treatment space, a noteworthy sector given the ongoing challenge of opioid-related adversities. By acquiring SiteOne Therapeutics, Eli Lilly is not only expanding its portfolio but also reinforcing its strategic commitment to offering effective alternatives in pain management. This acquisition aligns with the company's broader strategy to pioneer non-opioid solutions, providing safer methods for pain relief amidst increasing demand for innovative medical interventions.